Zhou J, Zhou X G, Wang J W, Zhou H, Dong J
Department of Orthopaedic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Bone Joint Res. 2018 Jan;7(1):46-57. doi: 10.1302/2046-3758.71.BJR-2017-0129.R2.
In the present study, we aimed to assess whether gelatin/β-tricalcium phosphate (β-TCP) composite porous scaffolds could be used as a local controlled release system for vancomycin. We also investigated the efficiency of the scaffolds in eliminating infections and repairing osteomyelitis defects in rabbits.
The gelatin scaffolds containing differing amounts of of β-TCP (0%, 10%, 30% and 50%) were prepared for controlled release of vancomycin and were labelled G-TCP0, G-TCP1, G-TCP3 and G-TCP5, respectively. The Kirby-Bauer method was used to examine the release profile. Chronic osteomyelitis models of rabbits were established. After thorough debridement, the osteomyelitis defects were implanted with the scaffolds. Radiographs and histological examinations were carried out to investigate the efficiency of eliminating infections and repairing bone defects.
The prepared gelatin/β-TCP scaffolds exhibited a homogeneously interconnected 3D porous structure. The G-TCP0 scaffold exhibited the longest duration of vancomycin release with a release duration of eight weeks. With the increase of β-TCP contents, the release duration of the β-TCP-containing composite scaffolds was decreased. The complete release of vancomycin from the G-TCP5 scaffold was achieved within three weeks. In the treatment of osteomyelitis defects in rabbits, the G-TCP3 scaffold showed the most efficacious performance in eliminating infections and repairing bone defects.
The composite scaffolds could achieve local therapeutic drug levels over an extended duration. The G-TCP3 scaffold possessed the optimal porosity, interconnection and controlled release performance. Therefore, this scaffold could potentially be used in the treatment of chronic osteomyelitis defects.: J. Zhou, X. G. Zhou, J. W. Wang, H. Zhou, J. Dong. Treatment of osteomyelitis defects by a vancomycin-loaded gelatin/β-tricalcium phosphate composite scaffold. 2018;7:46-57. DOI: 10.1302/2046-3758.71.BJR-2017-0129.R2.
在本研究中，我们旨在评估明胶/β-磷酸三钙（β-TCP）复合多孔支架是否可作为万古霉素的局部控释系统。我们还研究了该支架在消除兔感染和修复骨髓炎骨缺损方面的效果。
制备含有不同含量β-TCP（0%、10%、30%和50%）的明胶支架用于万古霉素的控释，分别标记为G-TCP0、G-TCP1、G-TCP3和G-TCP5。采用 Kirby-Bauer 法检测释放曲线。建立兔慢性骨髓炎模型。彻底清创后，将支架植入骨髓炎骨缺损处。进行 X 线片和组织学检查以研究消除感染和修复骨缺损的效果。
制备的明胶/β-TCP 支架呈现出均匀互连的三维多孔结构。G-TCP0 支架的万古霉素释放持续时间最长，为八周。随着β-TCP 含量的增加，含β-TCP 复合支架的释放持续时间缩短。G-TCP5 支架在三周内实现了万古霉素的完全释放。在治疗兔骨髓炎骨缺损时，G-TCP3 支架在消除感染和修复骨缺损方面表现出最有效的性能。
复合支架可在较长时间内达到局部治疗药物水平。G-TCP3 支架具有最佳的孔隙率、互连性和控释性能。因此，该支架有可能用于治疗慢性骨髓炎骨缺损。：周 J、周 X.G.、王 J.W.、周 H、董 J。载万古霉素明胶/β-磷酸三钙复合支架治疗骨髓炎骨缺损。2018；7：46 - 57。DOI：10.1302/2046 - 3758.71.BJR - 2017 - 0129.R2。
